Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS ...

A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline. Among those surveyed, 83 percent ...

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

The University of California, Berkeley’s incubator for life sciences Bakar Labs announced construction for a new research and ...

EVERSANA’s president of compliance services Vikram Anand spoke with Pharmaceutical Executive about the launch of EVERSANA ...